ReviewPathogens and disease2016
Microbiota and pathogen 'pas de deux': setting up and breaking down barriers to intestinal infection.
Review in Pathogens and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Beyond the gut microbe: Rethinking infection, microbiome harmony, and the one-health continuum.World journal of gastrointestinal pharmacology and therapeutics · 2026Review
- The influence of washed microbiota transplantation on menstruation in female patients of childbearing age.Frontiers in endocrinology · 2026Article
- Interaction BetweenCurrent pharmaceutical biotechnology · 2026Review
- Microbiota-Accessible Borates as Novel and Emerging Prebiotics for Healthy Longevity: Current Research Trends and Perspectives.Pharmaceuticals (Basel, Switzerland) · 2025Review
- Healthcare-Associated Infections: The Role of Microbial and Environmental Factors in Infection Control-A Narrative Review.Infectious diseases and therapy · 2025Review
- Towards a Rational Basis for the Selection of Probiotics to Improve Silkworm Health and Performance.Insects · 2025Review
- Insights into human respiratory microbiome under dysbiosis and its analysis tool.Frontiers in microbiomes · 2025Review
- Microbiota modulation for infectious complications following allogeneic hematopoietic stem cell transplantation in pediatric hematological malignancies.Frontiers in pediatrics · 2025Review
- Coprophagia in early life tunes expression of immune genes after weaning in rabbit ileum.Scientific reports · 2024Article
- The gut-liver axis in sepsis: interaction mechanisms and therapeutic potential.Critical care (London, England) · 2022Review
- A pathogen-specific sRNA influences enterohemorrhagic Escherichia coli fitness and virulence in part by direct interaction with the transcript encoding the ethanolamine utilization regulatory factor EutR.Nucleic acids research · 2021Article
- Dynamic Interplay Between Microbiota and Mucosal Immunity in Early Shaping of Asthma and its Implication for the COVID-19 Pandemic.Journal of asthma and allergy · 2020Review
- Plant-Derived Inhibitors of AHL-Mediated Quorum Sensing in Bacteria: Modes of Action.International journal of molecular sciences · 2019Review
- Gut Leakage of Fungal-Derived Inflammatory Mediators: Part of a Gut-Liver-Kidney Axis in Bacterial Sepsis.Digestive diseases and sciences · 2019Review
- QseC Signaling in the Outbreak O104:H4Journal of bacteriology · 2019Article
- Microbiome predictors of dysbiosis and VRE decolonization in patients with recurrentAIMS microbiology · 2019Article
- Article
- MouR controls the expression of the Listeria monocytogenes Agr system and mediates virulence.Nucleic acids research · 2018Article
- Article
- Editorial: The sum of all defenses: tolerance + resistance.Pathogens and disease · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
The gut microbiota plays essential roles in human health and disease. In this review, we focus on the role of the intestinal microbiota in promoting resistance to infection by bacterial pathogens as well as how pathogens overcome this barrier. We discuss how the resident microbiota restricts growth and colonization of invading pathogens by limiting availability of nutrients and through generation of a hostile environment. Additionally, we examine how microbiota-derived signaling molecules interfere with bacterial virulence. In turn, we discuss how pathogens exploit non-competitive metabolites to replicate in vivo as well as to precisely control virulence and cause disease. This bacterial two step of creating and overcoming challenges important in preventing and establishing infection highlights the complexities of elucidating interactions between the commensal bacteria and pathogens. Better understanding of microbiota-pathogen interplay will have significant implications for developing novel therapeutics to treat infectious diseases.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.